Coronavirus Clinical Trial
Official title:
A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers
Verified date | July 2023 |
Source | University of Oxford |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A phase I/II single-blinded, randomised, multi-centre study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers aged 18-55 years. The vaccine will be administered intramuscularly (IM) into the deltoid region of the arm
Status | Active, not recruiting |
Enrollment | 1090 |
Est. completion date | March 31, 2024 |
Est. primary completion date | March 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria The volunteer must satisfy all the following criteria to be eligible for the study: - Healthy adults aged 18-55 years. - Able and willing (in the Investigator's opinion) to comply with all study requirements (participants must not rely on public transport or taxis). - Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner and access all medical records when relevant to study procedures. - For females only, willingness to practice continuous effective contraception (see below) during the study and a negative pregnancy test on the day(s) of screening and vaccination. - Agreement to refrain from blood donation during the course of the study. - Provide written informed consent. Exclusion Criteria The volunteer may not enter the study if any of the following apply: - Planned receipt of any vaccine other than the study intervention within 30 days before and after each study vaccination .with the exception of the licensed seasonal influenza vaccination and the licensed pneumococcal vaccine. Participants will be encouraged to receive this vaccination at least 7 days before or after their study vaccine. - Prior receipt of an investigational or licensed vaccine likely to impact on interpretation of the trial data (e.g. Adenovirus vectored vaccines, any coronavirus vaccines). - Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate. - Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent severe infections and use of immunosuppressant medication within the past 6 months, except topical steroids or short-term oral steroids (course lasting <14 days) . - Any autoimmune conditions, except mild psoriasis, well-controlled autoimmune thyroid disease, vitiligo or stable coeliac disease not requiring immunosuppressive or immunomodulatory therapy. - History of allergic disease or reactions likely to be exacerbated by any component of the ChAdOx1 nCoV-19 or MenACWY vaccines. - Any history of angioedema . - Any history of anaphylaxis . - Pregnancy, lactation or willingness/intention to become pregnant during the study. - History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ). - History of serious psychiatric condition likely to affect participation in the study (e.g. ongoing severe depression, history of admission to an in-patient psychiatric facility, recent suicidal ideation, history of suicide attempt, bipolar disorder, personality disorder, alcohol and drug dependency, severe eating disorder, psychosis, use of mood stabilisers or antipsychotic medication). - Bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture. - Any other serious chronic illness requiring hospital specialist supervision. - Chronic respiratory diseases, including mild asthma (resolved childhood asthma is allowed) - Chronic cardiovascular disease (including hypertension), gastrointestinal disease, liver disease (except Gilberts Syndrome), renal disease, endocrine disorder (including diabetes) and neurological illness (excluding migraine) - Seriously overweight (BMI=40 Kg/m2) or underweight (BMI=18 Kg/m2) - Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week. - Suspected or known injecting drug abuse in the 5 years preceding enrolment. - Any clinically significant abnormal finding on screening biochemistry, haematology blood tests or urinalysis. - Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data. - History of laboratory confirmed COVID-19. - New onset of fever or a cough or shortness of breath or anosmia/ageusia since February 2020. Should a reliable test become available, this exclusion criteria will be replaced with seropositivity for SARS-CoV-2 before enrolment. - Those who have been at high risk of exposure before enrolment, including but not limited to: close contacts of confirmed COVID-19 cases, anyone who had to self-isolate as a result of a symptomatic household member, frontline healthcare professionals working in A&E, ICU and other higher risk areas. Should a reliable test become available, this exclusion criteria will be replaced with seropositivity for SARS-CoV-2 before enrolment. - Living in the same household as any vulnerable groups at risk of severe COVID-19 disease (as per Public Health England guidance) Additional exclusion criteria (subset of participants receiving Paracetamol in group 4 only) • History of allergic disease or reactions likely to be exacerbated by Paracetamol Re-vaccination exclusion criteria: The following AEs associated with any vaccine, or identified on or before the day of vaccination constitute absolute contraindications to further administration of an IMP to the volunteer in question. If any of these events occur during the study, the subject will not be eligible to receive a booster dose and will be followed up by the clinical team or their GP until resolution or stabilisation of the event: - Anaphylactic reaction following administration of vaccine - Pregnancy. An exception to this will be prior to receipt of a booster dose at extra visit B. If a pregnant woman has discussed vaccination with their usual clinician (e.g. GP) and chooses to receive a COVID-19 vaccination, this may be administered by the trial team as part of extra visit B or as part of the provision of treatment to controls - Any AE that in the opinion of the Investigator may affect the safety of the participant or the interpretation of the study results |
Country | Name | City | State |
---|---|---|---|
United Kingdom | University Hospitals Bristol and Weston NHS Foundation Trust | Bristol | |
United Kingdom | Imperial College Healthcare NHS Trust | London | |
United Kingdom | St Georges University Hospital NHS Foundation Trust | London | |
United Kingdom | CCVTM, University of Oxford, Churchill Hospital | Oxford | |
United Kingdom | John Radcliffe Hospital | Oxford | |
United Kingdom | University Hospital Southampton NHS Foundation Trust | Southampton | Hampshire |
Lead Sponsor | Collaborator |
---|---|
University of Oxford |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19 through Virus neutralising antibody assays | Virus neutralising antibody (NAb) assays against live and/or pseudotype SARS-CoV-2 virus | 6 months | |
Other | Assess safety, reactogenicity, immunogenicity and efficacy endpoints, for participants receiving prophylactic paracetamol | All safety, reactogenicity, immunogenicity and efficacy endpoints | 6 months | |
Other | Assess immunogenicity of ChAdOx1 nCoV-19 given as homologous prime-boost | Quantify antibodies against SARS-CoV-2 spike protein (seroconversion rates) post boost | 6 months | |
Other | Compare viral shedding on stool samples of SARS-CoV-2 PCR or NAAT positive individuals | Differences in viral shedding on stool between vaccine and comparator arms at 7 days and beyond post SARS-CoV-2 PCR or NAAT positivity | 6 months | |
Other | Assess immunogenicity of a delayed three dose ChAdOx1 nCoV-19 schedule | Quantify antibodies against SARS-CoV-2 spike protein (seroconversion rates) post boost | Blood samples drawn at LV14, LV28 and LV182 | |
Other | assess immunological correlates of protection in relation to occurrence of COVID-19 disease in ChAdOx1 nCoV-19 recipients | Immunological endpoints (antibody & cellular responses to SARS-COV2 spike protein) and COVID-19 disease endpoints (SARS-COV2 PCR positivity plus symptoms) in ChAdOx1 nCoV-19 recipients | Throughout the study, average of 18 months | |
Primary | Assess efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19: Number of virologically confirmed (PCR positive) symptomatic cases | Number of virologically confirmed (PCR or NAAT positive) symptomatic cases of COVID-19 | 6 months | |
Primary | Assess the safety of the candidate vaccine ChAdOx1 nCoV: Occurrence of serious adverse events (SAEs) | Occurrence of serious adverse events (SAEs) throughout the study until a cutoff date of 1st July 2021 or 6 months post late vaccination visit, whichever is latest | Throughout the study, average of 18 months | |
Secondary | Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited local reactogenicity signs and symptoms | Occurrence of solicited local reactogenicity signs and symptoms for 7 days following vaccination | 7 days following vaccination | |
Secondary | Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited systemic reactogenicity signs and symptoms | Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following vaccination | 7 days following vaccination | |
Secondary | Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of unsolicited adverse events (AEs) | Occurrence of unsolicited adverse events (AEs) for 28 days following vaccination (7 days following vaccination for groups 1c, 1d, 5a & 5b) | 7 or 28 days following vaccination | |
Secondary | Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV through standard blood tests | Change from baseline for safety laboratory measures (haematology and biochemistry blood results) | 6 months | |
Secondary | Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV by measuring the number of disease enhancement episodes | Occurrence of disease enhancement episodes | 6 months | |
Secondary | Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by hospital admissions | Number of hospital admissions associated with COVID-19 | 6 months | |
Secondary | Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by ICU admissions | Number of intensive care unit admissions associated with COVID-19 | 6 months | |
Secondary | Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by COVID-19 related deaths | Number of deaths associated with COVID-19 | 6 months | |
Secondary | Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 | Occurrence of severe COVID-19 disease (defined according to clinical severity scales) | 6 months | |
Secondary | Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by measuring seroconversion rates | Proportion of people who become seropositive for non-Spike SARS-CoV-2 antigens during the study | 6 months | |
Secondary | Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19 through ELISpot assays | Interferon-gamma (IFN-?) enzyme-linked immunospot (ELISpot) responses to SARS-CoV-2 spike protein | 6 months | |
Secondary | Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19 | Quantify antibodies against SARS-CoV-2 spike protein (seroconversion rates) | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05065827 -
Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
|
||
Recruiting |
NCT05359770 -
Association of Inspiratory Muscle Training With HD-tDCS for Assistance to Patients With Long Covid-19
|
N/A | |
Completed |
NCT04515147 -
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
|
Phase 2 | |
Not yet recruiting |
NCT06025812 -
Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)
|
N/A | |
Recruiting |
NCT05289115 -
Protocol for Assistance to Patients With Long Covid-19 Undergoing Treatment With HD-tDCS
|
N/A | |
Completed |
NCT04953078 -
A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19
|
Phase 1 | |
Completed |
NCT04779138 -
Increasing Vaccine Uptake in Underresourced Public Housing Areas
|
N/A | |
Not yet recruiting |
NCT05868239 -
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
|
N/A | |
Completed |
NCT04818164 -
Prone Position Improves End-Expiratory Lung Volumes in COVID-19 Acute Respiratory Distress Syndrome
|
||
Completed |
NCT04690413 -
NOWDx Test for the Detection of Antibodies to COVID-19
|
N/A | |
Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
Completed |
NCT04572399 -
UVA Light Device to Treat COVID-19
|
N/A | |
Recruiting |
NCT04610567 -
Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04772170 -
Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies
|
||
Recruiting |
NCT04581954 -
Inflammatory Signal Inhibitors for COVID-19 (MATIS)
|
Phase 1/Phase 2 | |
Completed |
NCT04405934 -
COG-UK Project Hospital-Onset COVID-19 Infections Study
|
N/A | |
Enrolling by invitation |
NCT04484025 -
SPI-1005 Treatment in Moderate COVID-19 Patients
|
Phase 2 | |
Completed |
NCT05572840 -
Wear Your Mask, Wash Your Hands, Don't Get COVID-19
|
N/A | |
Withdrawn |
NCT04838847 -
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
|
Phase 3 | |
Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 |